Group 1 - The 2025 China International Service Trade Fair (CIFTIS) opened on September 10, showcasing a vibrant array of international participation and innovative technologies [1][3] - In the first half of the year, China's service trade import and export totaled 3.9 trillion yuan, marking an 8% year-on-year increase, the highest for the same period in history [1] - The fair features over 2,000 enterprises, including nearly 500 Fortune 500 companies, with an international participation rate exceeding 20% [4] Group 2 - Australia is the guest country for this year's fair, with nearly 60 institutions and enterprises participating, highlighting the strength of China-Australia cooperation [3][4] - Norway's participation includes a focus on sustainable aquaculture, with a company preparing to enter the Chinese market with Atlantic salmon products [4][5] - Johnson & Johnson has introduced 40 innovative drugs to the Chinese market, with 32 included in the national medical insurance, emphasizing the company's commitment to patient-centered healthcare [5][6] Group 3 - The fair features advanced healthcare technologies, including robotic applications in surgery, which significantly enhance operational precision and patient safety [8] - The education service section showcases AI-driven educational tools, attracting interest from educators and industry professionals [10] - A total of 113 enterprises are set to launch 198 new products and achievements during the fair, indicating a strong focus on innovation and collaboration in the service trade sector [10]

2025年1月27日，国家药品监督管理局批准了 强生子公司——Biosense Webster, Inc. 的 心脏脉冲电场消融系统 （国械注进20253010069）和 一次性使用磁定位心脏 脉冲电场消融导管 （国械注进20253010070） 2个创新产品注册申请。 急性 Varipulse系统由 Varipulse 消融导管 和 TruPulse 发生器 组成，为在竞争激烈的市场中脱颖而出，还能与强生的Carto 3三维标测系统完美兼容。作为 首个集成 Carto 3 的脉冲场消融技术 ，Varipulse通过实时可视化和反馈，实现了操作流程的直观性和重复性。 该系统主要用于治疗 药物难治性、复发性、症状性的阵发性房颤 ，利用脉冲电场的非热效应原理进行房颤治疗，与传统的射频消融及冷冻消融产品相比，可实现 对心肌组织的选择性破坏，避免温度传递导致的周围组织损伤风险。 Varipulse系统于 2021年2月进入创新通道 ，随后已分别于 2024年1月、2024年2月、2024年11月和2025年1月获得日本PDMA、欧盟CE、美国FDA和我国NMPA的批准 ，在全球范围内已成功应用于超过3000台手术，并 ...